Clinical trial

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

NCT04959305

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention HCP1803-3 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention RLD2003 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention RLD2004 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention RLD2005 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention HPP2003-3 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention HPP2005 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-04-22

PhasePHASE2

Conditions

Hypertensionunresolved

Interventions

HCP1803-3DRUG

RLD2003DRUG

RLD2004DRUG

RLD2005DRUG

HPP2003-3DRUG

HPP2005DRUG

Sponsors & collaborators

Hanmi Pharmaceutical Company Limitedlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04959305 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.